Blarcamesine Shows Promise in Alzheimer’s Treatment
Anavex Life Sciences has recently reported promising results from its Phase 2b/3 trial of blarcamesine, an investigational agent for treating early Alzheimer’s disease. The trial demonstrated significant reductions in pathological amyloid-ß levels and a slowing of brain atrophy, marking a notable advancement in Alzheimer’s research. Anavex study included 508 participants with early symptomatic Alzheimer’s, randomized […]